The tweet was deleted by the author.
But we saved everything 🙂.
Definium Therapeutics announced it is presenting positive topline data from its DT120 clinical program for the first time on a medical congress stage.
The company will share a combined presentation of clinical updates from studies including Panorama and Emerge at the Neuroscience Education Institute Congress this week.
View post on X Loading...
Definium Therapeutics has recently updated on Phase 3 studies of DT120 for depression and anxiety at a major neuropsychopharmacology event, according to a previous report. The company also announced plans to release Q3 2026 financial results following three positive Phase 3 topline results in late-stage trials, as detailed in an earlier announcement. Both updates reflect continued momentum in Definium’s clinical development programs.